Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Core Laboratories (CLB) EBITDA Margin (2022 - 2026)

Core Laboratories filings provide 5 years of EBITDA Margin readings, the most recent being 4.47% for Q1 2026.

  • On a quarterly basis, EBITDA Margin fell 201.0% to 4.47% in Q1 2026 year-over-year; TTM through Mar 2026 was 4.07%, a 920.0% decrease, with the full-year FY2025 number at 4.54%, down 939.0% from a year prior.
  • EBITDA Margin hit 4.47% in Q1 2026 for Core Laboratories, up from 19.81% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 18.18% in Q3 2025 to a low of 21.97% in Q4 2023.
  • Median EBITDA Margin over the past 5 years was 14.1% (2024), compared with a mean of 8.83%.
  • Biggest five-year swings in EBITDA Margin: plummeted -3728bps in 2023 and later surged 3568bps in 2024.
  • Core Laboratories' EBITDA Margin stood at 15.3% in 2022, then crashed by -244bps to 21.97% in 2023, then soared by 162bps to 13.71% in 2024, then crashed by -245bps to 19.81% in 2025, then skyrocketed by 123bps to 4.47% in 2026.
  • The last three reported values for EBITDA Margin were 4.47% (Q1 2026), 19.81% (Q4 2025), and 18.18% (Q3 2025) per Business Quant data.